Skip to content

BENITEC BIOPHARMA INC.

BNTC

CIK 0001808898

← back to feed
Revenue (TTM)
$0
−42.2% YoY Q3 May 2026
Net Income (TTM)
−$47.24M
−74.0% YoY Q3 May 2026
EPS Diluted (TTM)
−$1.10
−16.7% YoY Q3 May 2026
Gross Margin
—
Q3 May 2026
Operating Margin
—
Q3 May 2026
Net Margin
—
Q3 May 2026
Free Cash Flow (TTM)
−$16.58M
Q3 May 2026
Cash
$184.76M
Q3 May 2026
Total Debt
—
Q3 May 2026
Shares Outstanding
34.35M sh
Q3 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings